TrialAntimicrobial agents and chemotherapy2014

A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.

F Joel Leong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.